Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Tietze, LF; Herzig, T; Fecher, A; Haunert, F; Schuberth, I
   Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues forantibody-directed enzyme tumor therapy
   CHEMBIOCHEM
   
   L.F. Tietze et al., "Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues forantibody-directed enzyme tumor therapy", CHEMBIOCHEM, 2(10), 2001, pp. 758-765
2. Damen, EWP; de Groot, FMH; Scheeren, HW
   Novel anthracycline prodrugs
   EXPERT OPINION ON THERAPEUTIC PATENTS
   
   E.W.P. Damen et al., "Novel anthracycline prodrugs", EXPERT OP T, 11(4), 2001, pp. 651-666
3. Rafii, F; Hehman, G; Lunsford, P
   Purification and characterization of an enzyme from Mycobacterium sp Pyr-1, with nitroreductase activity and an N-terminal sequence similar to lipoamide dehydrogenase
   ARCHIVES OF MICROBIOLOGY
   
   F. Rafii et al., "Purification and characterization of an enzyme from Mycobacterium sp Pyr-1, with nitroreductase activity and an N-terminal sequence similar to lipoamide dehydrogenase", ARCH MICROB, 176(5), 2001, pp. 381-385
4. Rogozin, V; Edan, Y; Flash, T
   A real-time trajectory modification algorithm
   ROBOTICA
   
   V. Rogozin et al., "A real-time trajectory modification algorithm", ROBOTICA, 19, 2001, pp. 395-405
5. Denny, WA
   Prodrug strategies in cancer therapy
   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
   
   W.A. Denny, "Prodrug strategies in cancer therapy", EUR J MED C, 36(7-8), 2001, pp. 577-595
6. Monneret, C
   Recent developments in the field of antitumour anthracyclines
   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
   
   C. Monneret, "Recent developments in the field of antitumour anthracyclines", EUR J MED C, 36(6), 2001, pp. 483-493
7. Bloss, R
   Adept focuses on acquisitions to secure new markets
   INDUSTRIAL ROBOT
   
   R. Bloss, "Adept focuses on acquisitions to secure new markets", IND ROBOT, 28(1), 2001, pp. 21-23
8. Shabat, D; Lode, HN; Pertl, U; Reisfeld, RA; Rader, C; Lerner, RA; Barbas, CF
   In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy
   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
   
   D. Shabat et al., "In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy", P NAS US, 98(13), 2001, pp. 7528-7533
9. Chen, BM; Cheng, TL; Tzou, SC; Roffler, SR
   Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy
   INTERNATIONAL JOURNAL OF CANCER
   
   B.M. Chen et al., "Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy", INT J CANC, 94(6), 2001, pp. 850-858
10. Houba, PHJ; Boven, E; van der Meulen-Muileman, IH; Leenders, RGG; Scheeren, JW; Pinedo, HM; Haisma, HJ
    Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate
    INTERNATIONAL JOURNAL OF CANCER
    
    P.H.J. Houba et al., "Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate", INT J CANC, 91(4), 2001, pp. 550-554
11. Azoulay, M; Chalard, F; Gesson, JP; Florent, JC; Monneret, C
    2-nitro and 4-nitro-quinone-methides are not irreversible inhibitors of bovine beta-glucuronidase
    CARBOHYDRATE RESEARCH
    
    M. Azoulay et al., "2-nitro and 4-nitro-quinone-methides are not irreversible inhibitors of bovine beta-glucuronidase", CARBOHY RES, 332(2), 2001, pp. 151-156
12. Satchi, R; Connors, TA; Duncan, R
    PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsinB and PK1 as a model combination
    BRITISH JOURNAL OF CANCER
    
    R. Satchi et al., "PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsinB and PK1 as a model combination", BR J CANC, 85(7), 2001, pp. 1070-1076
13. Webley, SD; Francis, RJ; Pedley, RB; Sharma, SK; Begent, RHJ; Hartley, JA; Hochhauser, D
    Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material
    BRITISH JOURNAL OF CANCER
    
    S.D. Webley et al., "Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material", BR J CANC, 84(12), 2001, pp. 1671-1676
14. Folkes, LK; Wardman, P
    Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy
    BIOCHEMICAL PHARMACOLOGY
    
    L.K. Folkes e P. Wardman, "Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy", BIOCH PHARM, 61(2), 2001, pp. 129-136
15. Nivinskas, H; Koder, RL; Anusevicius, Z; Sarlauskas, J; Miller, AF; Cenas, N
    Quantitative structure-activity relationships in two-electron reduction ofnitroaromatic compounds by Enterobacter cloacae NAD(P)H : nitroreductase
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    H. Nivinskas et al., "Quantitative structure-activity relationships in two-electron reduction ofnitroaromatic compounds by Enterobacter cloacae NAD(P)H : nitroreductase", ARCH BIOCH, 385(1), 2001, pp. 170-178
16. Burke, PJ
    The potential use of carboxypeptidase G(2) in the treatment of cancer
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    P.J. Burke, "The potential use of carboxypeptidase G(2) in the treatment of cancer", EXPERT OP T, 10(2), 2000, pp. 209-214
17. Napier, MP; Sharma, SK; Springer, CJ; Bagshawe, KD; Green, AJ; Martin, J; Stribbling, SM; Cushen, N; O'Malley, D; Begent, RHJ
    Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of actionin colorectal carcinoma
    CLINICAL CANCER RESEARCH
    
    M.P. Napier et al., "Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of actionin colorectal carcinoma", CLIN CANC R, 6(3), 2000, pp. 765-772
18. Hu, LQ; Liu, B; Hacking, DR
    5 '-[2-(2-nitrophenyl)-2-methylpropionyl]-2 '-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: Synthesis, stability andreductive activation
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    L.Q. Hu et al., "5 '-[2-(2-nitrophenyl)-2-methylpropionyl]-2 '-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: Synthesis, stability andreductive activation", BIOORG MED, 10(8), 2000, pp. 797-800
19. Chester, KA; Mayer, A; Bhatia, J; Robson, L; Spencer, DIR; Cooke, SP; Flynn, AA; Sharma, SK; Boxer, G; Pedley, RB; Begent, RHJ
    Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    K.A. Chester et al., "Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer", CANC CHEMOT, 46, 2000, pp. S8-S12
20. Sykes, BM; Hay, MP; Bohinc-Herceg, D; Helsby, NA; O'Connor, CJ; Denny, WA
    Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates
    JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    
    B.M. Sykes et al., "Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates", J CHEM S P1, 10, 2000, pp. 1601-1608
21. Chester, KA; Bhatia, J; Boxer, G; Cooke, SP; Flynn, AA; Huhalov, A; Mayer, A; Pedley, RB; Robson, L; Sharma, SK; Spencer, DIR; Begent, RHJ
    Clinical applications of phage-derived sFvs and sFv fusion proteins
    DISEASE MARKERS
    
    K.A. Chester et al., "Clinical applications of phage-derived sFvs and sFv fusion proteins", DIS MARKER, 16(1-2), 2000, pp. 53-62
22. Parkinson, GN; Skelly, JV; Neidle, S
    Crystal structure of FMN-dependent nitroreductase from Escherichia coli B:A prodrug-activating enzyme
    JOURNAL OF MEDICINAL CHEMISTRY
    
    G.N. Parkinson et al., "Crystal structure of FMN-dependent nitroreductase from Escherichia coli B:A prodrug-activating enzyme", J MED CHEM, 43(20), 2000, pp. 3624-3631
23. Monks, NR; Calvete, JA; Curtin, NJ; Blakey, DC; East, SJ; Newell, DR
    Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
    BRITISH JOURNAL OF CANCER
    
    N.R. Monks et al., "Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)", BR J CANC, 83(2), 2000, pp. 267-269
24. Leenders, RGG; Damen, EWP; Bijsterveld, EJA; Scheeren, HW; Houba, PHJ; van der Meulen-Muileman, IH; Boven, E; Haisma, HJ
    Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy
    BIOORGANIC & MEDICINAL CHEMISTRY
    
    R.G.G. Leenders et al., "Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy", BIO MED CH, 7(8), 1999, pp. 1597-1610
25. Hay, MP; Sykes, BM; Denny, WA; Wilson, WR
    A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    M.P. Hay et al., "A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT", BIOORG MED, 9(15), 1999, pp. 2237-2242
26. Hay, MP; Sykes, BM; Denny, WA; O'Connor, CJ
    Substituent effects on the kinetics of reductively-initiated fragmentationof nitrobenzyl carbamates designed as triggers for bioreductive prodrugs
    JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    
    M.P. Hay et al., "Substituent effects on the kinetics of reductively-initiated fragmentationof nitrobenzyl carbamates designed as triggers for bioreductive prodrugs", J CHEM S P1, (19), 1999, pp. 2759-2770
27. Madec-Lougerstay, R; Florent, JC; Monneret, C
    Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy
    JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1
    
    R. Madec-Lougerstay et al., "Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy", J CHEM S P1, (10), 1999, pp. 1369-1375
28. Bakina, E; Farquhar, D
    Intensely cytotoxic anthracycline prodrugs: galactosides
    ANTI-CANCER DRUG DESIGN
    
    E. Bakina e D. Farquhar, "Intensely cytotoxic anthracycline prodrugs: galactosides", ANTI-CAN DR, 14(6), 1999, pp. 507-515
29. Niculescu-Duvaz, I; Friedlos, F; Niculescu-Duvaz, D; Davies, L; Springer, CJ
    Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)
    ANTI-CANCER DRUG DESIGN
    
    I. Niculescu-Duvaz et al., "Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)", ANTI-CAN DR, 14(6), 1999, pp. 517-538
30. Desbene, S; Van, HDT; Michel, S; Tillequin, F; Koch, M; Schmidt, F; Florent, JC; Monneret, C; Straub, R; Czech, J; Gerken, M; Bosslet, K
    Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy
    ANTI-CANCER DRUG DESIGN
    
    S. Desbene et al., "Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy", ANTI-CAN DR, 14(2), 1999, pp. 93-106
31. Dubowchik, GM; Walker, MA
    Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
    PHARMACOLOGY & THERAPEUTICS
    
    G.M. Dubowchik e M.A. Walker, "Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs", PHARM THERA, 83(2), 1999, pp. 67-123
32. Papot, S; Bachmann, C; Combaud, D; Gesson, JP
    Study of biscarbamates derived from 2-aminobenzylamines as models for alcohol prodrugs
    TETRAHEDRON
    
    S. Papot et al., "Study of biscarbamates derived from 2-aminobenzylamines as models for alcohol prodrugs", TETRAHEDRON, 55(15), 1999, pp. 4699-4708
33. Smyth, TP; O'Connor, MJ; O'Donnell, ME
    Extending the beta-lactamase-dependent prodrug armory: S-aminosulfeniminocephalosporins as dual-release prodrugs
    JOURNAL OF ORGANIC CHEMISTRY
    
    T.P. Smyth et al., "Extending the beta-lactamase-dependent prodrug armory: S-aminosulfeniminocephalosporins as dual-release prodrugs", J ORG CHEM, 64(9), 1999, pp. 3132-3138
34. Khan, TH; Eno-Amooquaye, EA; Searle, F; Browne, PJ; Osborn, HMI; Burke, PJ
    Novel inhibitors of carboxypeptidase G(2) (CPG(2)): Potential use in antibody-directed enzyme prodrug therapy
    JOURNAL OF MEDICINAL CHEMISTRY
    
    T.H. Khan et al., "Novel inhibitors of carboxypeptidase G(2) (CPG(2)): Potential use in antibody-directed enzyme prodrug therapy", J MED CHEM, 42(6), 1999, pp. 951-956
35. Mayer, A; Chester, KA; Flynn, AA; Begent, RHJ
    Taking engineered anti-CEA antibodies to the clinic
    JOURNAL OF IMMUNOLOGICAL METHODS
    
    A. Mayer et al., "Taking engineered anti-CEA antibodies to the clinic", J IMMUNOL M, 231(1-2), 1999, pp. 261-273
36. Cheng, TL; Chou, WC; Chen, BM; Chern, JW; Roffler, SR
    Characterization of an antineoplastic glucuronide prodrug
    BIOCHEMICAL PHARMACOLOGY
    
    T.L. Cheng et al., "Characterization of an antineoplastic glucuronide prodrug", BIOCH PHARM, 58(2), 1999, pp. 325-328
37. Fonseca, MJ; Haisma, HJ; Klaasen, S; Vingerhoeds, MH; Storm, G
    Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
    
    M.J. Fonseca et al., "Design of immuno-enzymosomes with maximum enzyme targeting capability: effect of the enzyme density on the enzyme targeting capability and cell binding properties", BBA-BIOMEMB, 1419(2), 1999, pp. 272-282
38. SCHMIDT F; FLORENT JC; MONNERET C
    SYNTHESIS AND STUDY OF A DIPYRIDAMOLE PRODRUG - APPLICATION OF THE ADEPT STRATEGY TO THE MDR RESISTANCE IN CANCER-CHEMOTHERAPY
    COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE II FASCICULE C-CHIMIE
    
    F. Schmidt et al., "SYNTHESIS AND STUDY OF A DIPYRIDAMOLE PRODRUG - APPLICATION OF THE ADEPT STRATEGY TO THE MDR RESISTANCE IN CANCER-CHEMOTHERAPY", COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE II FASCICULE C-CHIMIE, 1(7), 1998, pp. 421-424
39. KODER RL; MILLER AF
    OVEREXPRESSION, ISOTOPIC LABELING, AND SPECTRAL CHARACTERIZATION OF ENEROBACTER-CLOACAE NITROREDUCTASE
    Protein expression and purification
    
    R.L. Koder e A.F. Miller, "OVEREXPRESSION, ISOTOPIC LABELING, AND SPECTRAL CHARACTERIZATION OF ENEROBACTER-CLOACAE NITROREDUCTASE", Protein expression and purification, 13(1), 1998, pp. 53-60
40. FOLKES LK; CANDEIAS LP; WARDMAN P
    TOWARD TARGETED OXIDATION THERAPY OF CANCER - PEROXIDASE-CATALYZED CYTOTOXICITY OF INDOLE-3-ACETIC ACIDS
    International journal of radiation oncology, biology, physics
    
    L.K. Folkes et al., "TOWARD TARGETED OXIDATION THERAPY OF CANCER - PEROXIDASE-CATALYZED CYTOTOXICITY OF INDOLE-3-ACETIC ACIDS", International journal of radiation oncology, biology, physics, 42(4), 1998, pp. 917-920
41. HAISMA HJ; BRAKENHOFF RH; VANDERMEULENMUILEMAN I; PINEDO HM; BOVEN E
    CONSTRUCTION AND CHARACTERIZATION OF A FUSION PROTEIN OF SINGLE-CHAINANTI-CARCINOMA ANTIBODY 323 A3 AND HUMAN BETA-GLUCURONIDASE/
    Cancer immunology and immunotherapy
    
    H.J. Haisma et al., "CONSTRUCTION AND CHARACTERIZATION OF A FUSION PROTEIN OF SINGLE-CHAINANTI-CARCINOMA ANTIBODY 323 A3 AND HUMAN BETA-GLUCURONIDASE/", Cancer immunology and immunotherapy, 45(5), 1998, pp. 266-272
42. Desbene, S; Van, HDT; Michel, S; Koch, M; Tillequin, F; Fournier, G; Farjaudon, N; Monneret, C
    Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation
    ANTI-CANCER DRUG DESIGN
    
    S. Desbene et al., "Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation", ANTI-CAN DR, 13(8), 1998, pp. 955-968
43. Lougerstay-Madec, R; Florent, JC; Monneret, C; Nemati, F; Poupon, MF
    Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard
    ANTI-CANCER DRUG DESIGN
    
    R. Lougerstay-Madec et al., "Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard", ANTI-CAN DR, 13(8), 1998, pp. 995-1007
44. KODER RL; MILLER AF
    STEADY-STATE KINETIC MECHANISM, STEREOSPECIFICITY, SUBSTRATE AND INHIBITOR SPECIFICITY OF ENTEROBACTER-CLOACAE NITROREDUCTASE
    Biochimica et biophysica acta. Protein structure and molecular enzymology
    
    R.L. Koder e A.F. Miller, "STEADY-STATE KINETIC MECHANISM, STEREOSPECIFICITY, SUBSTRATE AND INHIBITOR SPECIFICITY OF ENTEROBACTER-CLOACAE NITROREDUCTASE", Biochimica et biophysica acta. Protein structure and molecular enzymology, 1387(1-2), 1998, pp. 395-405
45. Blackburn, GM; Datta, A; Denham, H; Wentworth, P
    Catalytic antibodies
    ADVANCES IN PHYSICAL ORGANIC CHEMISTRY, VOL 31
    
    G.M. Blackburn et al., "Catalytic antibodies", ADV PHYS O, 31, 1998, pp. 249-392
46. Denny, WA; Wilson, WR
    The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies
    JOURNAL OF PHARMACY AND PHARMACOLOGY
    
    W.A. Denny e W.R. Wilson, "The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies", J PHARM PHA, 50(4), 1998, pp. 387-394
47. SVENSSON HP; FRANK IS; BERRY KK; SENTER PD
    THERAPEUTIC EFFECTS OF MONOCLONAL ANTIBODY-BETA-LACTAMASE CONJUGATES IN COMBINATION WITH A NITROGEN-MUSTARD ANTICANCER PRODRUG IN MODELS OFHUMAN RENAL-CELL CARCINOMA
    Journal of medicinal chemistry
    
    H.P. Svensson et al., "THERAPEUTIC EFFECTS OF MONOCLONAL ANTIBODY-BETA-LACTAMASE CONJUGATES IN COMBINATION WITH A NITROGEN-MUSTARD ANTICANCER PRODRUG IN MODELS OFHUMAN RENAL-CELL CARCINOMA", Journal of medicinal chemistry, 41(9), 1998, pp. 1507-1512
48. FLORENT JC; DONG X; GAUDEL G; MITAKU S; MONNERET C; GESSON JP; JACQUESY JC; MONDON M; RENOUX B; ANDRIANOMENJANAHARY S; MICHEL S; KOCH M; TILLEQUIN F; GERKEN M; CZECH J; STRAUB R; BOSSLET K
    PRODRUGS OF ANTHRACYCLINES FOR USE IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY
    Journal of medicinal chemistry
    
    J.C. Florent et al., "PRODRUGS OF ANTHRACYCLINES FOR USE IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY", Journal of medicinal chemistry, 41(19), 1998, pp. 3572-3581
49. Niculescu-Duvaz, D; Niculescu-Duvaz, I; Friedlos, F; Martin, J; Spooner, R; Davies, L; Marais, R; Springer, CJ
    Self-immolative nitrogen mustard prodrugs for suicide gene therapy
    JOURNAL OF MEDICINAL CHEMISTRY
    
    D. Niculescu-Duvaz et al., "Self-immolative nitrogen mustard prodrugs for suicide gene therapy", J MED CHEM, 41(26), 1998, pp. 5297-5309
50. BLAKEY D
    ENZYME PRODRUG THERAPY OF CANCER
    Expert opinion on therapeutic patents
    
    D. Blakey, "ENZYME PRODRUG THERAPY OF CANCER", Expert opinion on therapeutic patents, 7(9), 1997, pp. 965-977
51. GUSTERSON B; CUI W; IWOBI M; CROMPTON MR; HAROLD G; HOBBS S; KAMALATI T; KNOX R; NEIL C; YULL F; HOWARD B; CLARK AJ
    SELECTIVE CELL ABLATION IN THE MAMMARY-GLAND OF TRANSGENIC MICE
    Endocrine-related cancer
    
    B. Gusterson et al., "SELECTIVE CELL ABLATION IN THE MAMMARY-GLAND OF TRANSGENIC MICE", Endocrine-related cancer, 4(1), 1997, pp. 67-74
52. SIEMERS NO; KERR DE; YARNOLD S; STEBBINS MR; VRUDHULA VM; HELLSTROM I; HELLSTROM KE; SENTER PD
    CONSTRUCTION, EXPRESSION, AND ACTIVITIES OF L49-SFV-BETA-LACTAMASE, ASINGLE-CHAIN ANTIBODY FUSION PROTEIN FOR ANTICANCER PRODRUG ACTIVATION
    Bioconjugate chemistry
    
    N.O. Siemers et al., "CONSTRUCTION, EXPRESSION, AND ACTIVITIES OF L49-SFV-BETA-LACTAMASE, ASINGLE-CHAIN ANTIBODY FUSION PROTEIN FOR ANTICANCER PRODRUG ACTIVATION", Bioconjugate chemistry, 8(4), 1997, pp. 510-519
53. LEMMON MJ; VANZIJL P; FOX ME; MAUCHLINE ML; GIACCIA AJ; MINTON NP; BROWN JM
    ANAEROBIC-BACTERIA AS A GENE DELIVERY SYSTEM THAT IS CONTROLLED BY THE TUMOR MICROENVIRONMENT
    Gene therapy
    
    M.J. Lemmon et al., "ANAEROBIC-BACTERIA AS A GENE DELIVERY SYSTEM THAT IS CONTROLLED BY THE TUMOR MICROENVIRONMENT", Gene therapy, 4(8), 1997, pp. 791-796
54. DRABEK D; GUY J; CRAIG R; GROSVELD F
    THE EXPRESSION OF BACTERIAL NITROREDUCTASE IN TRANSGENIC MICE RESULTSIN SPECIFIC CELL-KILLING BY THE PRODRUG CB1954
    Gene therapy
    
    D. Drabek et al., "THE EXPRESSION OF BACTERIAL NITROREDUCTASE IN TRANSGENIC MICE RESULTSIN SPECIFIC CELL-KILLING BY THE PRODRUG CB1954", Gene therapy, 4(2), 1997, pp. 93-100
55. CLARK AJ; IWOBI M; CUI W; CROMPTON M; HAROLD G; HOBBS S; KAMALATI T; KNOX R; NEIL C; YULL F; GUSTERSON B
    SELECTIVE CELL ABLATION IN TRANSGENIC MICE EXPRESSING ESCHERICHIA-COLI NITROREDUCTASE
    Gene therapy
    
    A.J. Clark et al., "SELECTIVE CELL ABLATION IN TRANSGENIC MICE EXPRESSING ESCHERICHIA-COLI NITROREDUCTASE", Gene therapy, 4(2), 1997, pp. 101-110
56. SIIM BG; DENNY WA; WILSON WR
    NITRO REDUCTION AS AN ELECTRONIC SWITCH FOR BIOREDUCTIVE DRUG ACTIVATION
    Oncology research
    
    B.G. Siim et al., "NITRO REDUCTION AS AN ELECTRONIC SWITCH FOR BIOREDUCTIVE DRUG ACTIVATION", Oncology research, 9(6-7), 1997, pp. 357-369
57. LEE M; SIMPSON JE; WOO S; KAENZIG C; ANLEZARK GM; ENOAMOOQUAYE E; BURKE PJ
    SYNTHESIS OF AN AMINOPROPYL, ANALOG OF THE EXPERIMENTAL ANTICANCER DRUG TALLIMUSTINE, AND ACTIVATION OF ITS 4-NITROBENZYLCARBAMOYL PRODRUG BY NITROREDUCTASE AND NADH
    Bioorganic & medicinal chemistry letters
    
    M. Lee et al., "SYNTHESIS OF AN AMINOPROPYL, ANALOG OF THE EXPERIMENTAL ANTICANCER DRUG TALLIMUSTINE, AND ACTIVATION OF ITS 4-NITROBENZYLCARBAMOYL PRODRUG BY NITROREDUCTASE AND NADH", Bioorganic & medicinal chemistry letters, 7(8), 1997, pp. 1065-1070
58. GREEN NK; YOUNGS DJ; NEOPTOLEMOS JP; FRIEDLOS F; KNOX RJ; SPRINGER CJ; ANLEZARK GM; MICHAEL NP; MELTON RG; FORD MJ; YOUNG LS; KERR DJ; SEARLE PF
    SENSITIZATION OF COLORECTAL AND PANCREATIC-CANCER CELL-LINES TO THE PRODRUG 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) BY RETROVIRAL TRANSDUCTION AND EXPRESSION OF THE ESCHERICHIA-COLI NITROREDUCTASE GENE
    Cancer gene therapy
    
    N.K. Green et al., "SENSITIZATION OF COLORECTAL AND PANCREATIC-CANCER CELL-LINES TO THE PRODRUG 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE (CB1954) BY RETROVIRAL TRANSDUCTION AND EXPRESSION OF THE ESCHERICHIA-COLI NITROREDUCTASE GENE", Cancer gene therapy, 4(4), 1997, pp. 229-238
59. STRIBBLING SM; MARTIN J; PEDLEY RB; BODEN JA; SHARMA SK; SPRINGER CJ
    BIODISTRIBUTION OF AN ANTIBODY-ENZYME CONJUGATE FOR ANTIBODY-DIRECTEDENZYME PRODRUG THERAPY IN NUDE-MICE BEARING A HUMAN COLON ADENOCARCINOMA XENOGRAFT
    Cancer chemotherapy and pharmacology
    
    S.M. Stribbling et al., "BIODISTRIBUTION OF AN ANTIBODY-ENZYME CONJUGATE FOR ANTIBODY-DIRECTEDENZYME PRODRUG THERAPY IN NUDE-MICE BEARING A HUMAN COLON ADENOCARCINOMA XENOGRAFT", Cancer chemotherapy and pharmacology, 40(4), 1997, pp. 277-284
60. MARTIN J; STRIBBLING SM; POON GK; BEGENT RHJ; NAPIER M; SHARMA SK; SPRINGER CJ
    ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY - PHARMACOKINETICS AND PLASMA-LEVELS OF PRODRUG AND DRUG IN A PHASE-I CLINICAL-TRIAL
    Cancer chemotherapy and pharmacology
    
    J. Martin et al., "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY - PHARMACOKINETICS AND PLASMA-LEVELS OF PRODRUG AND DRUG IN A PHASE-I CLINICAL-TRIAL", Cancer chemotherapy and pharmacology, 40(3), 1997, pp. 189-201
61. ER MJ; LIEW KC
    CONTROL OF ADEPT-ONE SCARA ROBOT USING NEURAL NETWORKS
    IEEE transactions on industrial electronics
    
    M.J. Er e K.C. Liew, "CONTROL OF ADEPT-ONE SCARA ROBOT USING NEURAL NETWORKS", IEEE transactions on industrial electronics, 44(6), 1997, pp. 762-768
62. NICULESCUDUVAZ I; SPRINGER CJ
    ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - A REVIEW
    Advanced drug delivery reviews
    
    I. Niculescuduvaz e C.J. Springer, "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - A REVIEW", Advanced drug delivery reviews, 26(2-3), 1997, pp. 151-172
63. STORM G; VINGERHOEDS MH; CROMMELIN DJA; HAISMA HJ
    IMMUNOLIPOSOMES BEARING ENZYMES (IMMUNO-ENZYMOSOMES) FOR SITE-SPECIFIC ACTIVATION OF ANTICANCER PRODRUGS
    Advanced drug delivery reviews
    
    G. Storm et al., "IMMUNOLIPOSOMES BEARING ENZYMES (IMMUNO-ENZYMOSOMES) FOR SITE-SPECIFIC ACTIVATION OF ANTICANCER PRODRUGS", Advanced drug delivery reviews, 24(2-3), 1997, pp. 225-231
64. RETTA BME; BURKE PJ; PHOTIOU A; MELTON RG; ENOAMOOQUAYE E
    ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - EVIDENCE FOR A BYSTANDER EFFECT IN-VITRO
    International journal of oncology
    
    B.M.E. Retta et al., "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - EVIDENCE FOR A BYSTANDER EFFECT IN-VITRO", International journal of oncology, 9(3), 1996, pp. 567-570
65. BAILEY SM; KNOX RJ; HOBBS SM; JENKINS TC; MAUGER AB; MELTON RG; BURKE PJ; CONNORS TA; HART IR
    INVESTIGATION OF ALTERNATIVE PRODRUGS FOR USE WITH ESCHERICHIA-COLI NITROREDUCTASE IN SUICIDE GENE APPROACHES TO CANCER-THERAPY
    Gene therapy
    
    S.M. Bailey et al., "INVESTIGATION OF ALTERNATIVE PRODRUGS FOR USE WITH ESCHERICHIA-COLI NITROREDUCTASE IN SUICIDE GENE APPROACHES TO CANCER-THERAPY", Gene therapy, 3(12), 1996, pp. 1143-1150
66. TERCEL M; DENNY WA; WILSON WR
    A NOVEL NITROSUBSTITUTED SECO-CI - APPLICATION AS A REDUCTIVELY ACTIVATED ADEPT PRODRUG
    Bioorganic & medicinal chemistry letters
    
    M. Tercel et al., "A NOVEL NITROSUBSTITUTED SECO-CI - APPLICATION AS A REDUCTIVELY ACTIVATED ADEPT PRODRUG", Bioorganic & medicinal chemistry letters, 6(22), 1996, pp. 2741-2744
67. CONNORS TA
    IS THERE A FUTURE FOR CANCER-CHEMOTHERAPY - THE CLAVEL,MICHEL LECTURE
    Annals of oncology
    
    T.A. Connors, "IS THERE A FUTURE FOR CANCER-CHEMOTHERAPY - THE CLAVEL,MICHEL LECTURE", Annals of oncology, 7(5), 1996, pp. 445-452
68. VINGERHOEDS MH; HAISMA HJ; BELLIOT SO; SMIT RHP; CROMMELIN DJA; STORM G
    IMMUNOLIPOSOMES AS ENZYME-CARRIERS (IMMUNO-ENZYMOSOMES) FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - OPTIMIZATION OF PRODRUG ACTIVATING CAPACITY
    Pharmaceutical research
    
    M.H. Vingerhoeds et al., "IMMUNOLIPOSOMES AS ENZYME-CARRIERS (IMMUNO-ENZYMOSOMES) FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - OPTIMIZATION OF PRODRUG ACTIVATING CAPACITY", Pharmaceutical research, 13(4), 1996, pp. 604-610
69. SPRINGER CJ; BAVETSIAS V; JACKMAN AL; BOYLE FT; MARSHALL D; PEDLEY RB; BISSET GMF
    PRODRUGS OF THYMIDYLATE SYNTHASE INHIBITORS - POTENTIAL FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)
    Anti-cancer drug design
    
    C.J. Springer et al., "PRODRUGS OF THYMIDYLATE SYNTHASE INHIBITORS - POTENTIAL FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)", Anti-cancer drug design, 11(8), 1996, pp. 625-636
70. ATWELL GJ; BOYD M; PALMER BD; ANDERSON RF; PULLEN SM; WILSON WR; DENNY WA
    SYNTHESIS AND EVALUATION OF 4-SUBSTITUTED ANALOGS OF 5-[N,N-BIS(2-CHLOROETHYL)AMINO]2-NITROBENZAMIDE AS BIOREDUCTIVELY ACTIVATED PRODRUGS USING AN ESCHERICHIA-COLI NITROREDUCTASE
    Anti-cancer drug design
    
    G.J. Atwell et al., "SYNTHESIS AND EVALUATION OF 4-SUBSTITUTED ANALOGS OF 5-[N,N-BIS(2-CHLOROETHYL)AMINO]2-NITROBENZAMIDE AS BIOREDUCTIVELY ACTIVATED PRODRUGS USING AN ESCHERICHIA-COLI NITROREDUCTASE", Anti-cancer drug design, 11(7), 1996, pp. 553-567
71. SHERWOOD RF
    ADVANCED DRUG-DELIVERY REVIEWS - ENZYME PRODRUG THERAPY
    Advanced drug delivery reviews
    
    R.F. Sherwood, "ADVANCED DRUG-DELIVERY REVIEWS - ENZYME PRODRUG THERAPY", Advanced drug delivery reviews, 22(3), 1996, pp. 269-288
72. MELTON RG
    PREPARATION AND PURIFICATION OF ANTIBODY-ENZYME CONJUGATES FOR THERAPEUTIC APPLICATIONS
    Advanced drug delivery reviews
    
    R.G. Melton, "PREPARATION AND PURIFICATION OF ANTIBODY-ENZYME CONJUGATES FOR THERAPEUTIC APPLICATIONS", Advanced drug delivery reviews, 22(3), 1996, pp. 289-301
73. CHESTER KA; HAWKINS RE
    OPPORTUNITIES WITH PHAGE TECHNOLOGY AND ANTIBODY ENGINEERING OF FUSION PROTEINS
    Advanced drug delivery reviews
    
    K.A. Chester e R.E. Hawkins, "OPPORTUNITIES WITH PHAGE TECHNOLOGY AND ANTIBODY ENGINEERING OF FUSION PROTEINS", Advanced drug delivery reviews, 22(3), 1996, pp. 303-313
74. SHARMA SK
    ACCELERATED CLEARANCE SYSTEMS
    Advanced drug delivery reviews
    
    S.K. Sharma, "ACCELERATED CLEARANCE SYSTEMS", Advanced drug delivery reviews, 22(3), 1996, pp. 315-324
75. BEGENT RHJ; BAGSHAWE KD
    BIODISTRIBUTION STUDIES
    Advanced drug delivery reviews
    
    R.H.J. Begent e K.D. Bagshawe, "BIODISTRIBUTION STUDIES", Advanced drug delivery reviews, 22(3), 1996, pp. 325-329
76. BURKE PJ
    ALKYLATING AGENT PRODRUGS FOR ADEPT
    Advanced drug delivery reviews
    
    P.J. Burke, "ALKYLATING AGENT PRODRUGS FOR ADEPT", Advanced drug delivery reviews, 22(3), 1996, pp. 331-340
77. SHARMA SK
    IMMUNE-RESPONSE IN ADEPT
    Advanced drug delivery reviews
    
    S.K. Sharma, "IMMUNE-RESPONSE IN ADEPT", Advanced drug delivery reviews, 22(3), 1996, pp. 369-376
78. KEARNEY AS
    PRODRUGS AND TARGETED DRUG-DELIVERY
    Advanced drug delivery reviews
    
    A.S. Kearney, "PRODRUGS AND TARGETED DRUG-DELIVERY", Advanced drug delivery reviews, 19(2), 1996, pp. 225-239
79. SINHABABU AK; THAKKER DR
    PRODRUGS OF ANTICANCER AGENTS
    Advanced drug delivery reviews
    
    A.K. Sinhababu e D.R. Thakker, "PRODRUGS OF ANTICANCER AGENTS", Advanced drug delivery reviews, 19(2), 1996, pp. 241-273
80. SCHUMACHER U; ADAM E; ZANGEMEISTERWITTKE U; GOSSRAU R
    HISTOCHEMISTRY OF THERAPEUTICALLY RELEVANT ENZYMES IN HUMAN TUMORS TRANSPLANTED INTO SEVERE COMBINED IMMUNODEFICIENT (SCID) MICE - NITRIC-OXIDE SYNTHASE - ASSOCIATED DIAPHORASE, BETA-D-GLUCURONIDASE AND NONSPECIFIC ALKALINE-PHOSPHATASE
    Acta histochemica
    
    U. Schumacher et al., "HISTOCHEMISTRY OF THERAPEUTICALLY RELEVANT ENZYMES IN HUMAN TUMORS TRANSPLANTED INTO SEVERE COMBINED IMMUNODEFICIENT (SCID) MICE - NITRIC-OXIDE SYNTHASE - ASSOCIATED DIAPHORASE, BETA-D-GLUCURONIDASE AND NONSPECIFIC ALKALINE-PHOSPHATASE", Acta histochemica, 98(4), 1996, pp. 381-387
81. SHARMA SK; BAGSHAWE KD; MELTON RG; BEGENT RHJ
    EFFECT OF CYCLOSPORINE ON IMMUNOGENICITY OF A BACTERIAL ENZYME CARBOXYPEPTIDASE G2 IN ADEPT
    Transplantation proceedings
    
    S.K. Sharma et al., "EFFECT OF CYCLOSPORINE ON IMMUNOGENICITY OF A BACTERIAL ENZYME CARBOXYPEPTIDASE G2 IN ADEPT", Transplantation proceedings, 28(6), 1996, pp. 3154-3155
82. LARDEN DW; CHEUNG HTA
    SYNTHESIS OF N-ALPHA-AMINOACYL DERIVATIVES OF MELPHALAN FOR POTENTIALUSE IN DRUG TARGETING
    Tetrahedron letters
    
    D.W. Larden e H.T.A. Cheung, "SYNTHESIS OF N-ALPHA-AMINOACYL DERIVATIVES OF MELPHALAN FOR POTENTIALUSE IN DRUG TARGETING", Tetrahedron letters, 37(42), 1996, pp. 7581-7582
83. LEENDERS RGG; RUYTENBEEK R; DAMEN EWP; SCHEEREN HW
    HIGHLY DIASTEREOSELECTIVE SYNTHESIS OF ANOMERIC BETA-O-GLYCOPYRANOSYLCARBAMATES FROM ISOCYANATES
    Synthesis
    
    R.G.G. Leenders et al., "HIGHLY DIASTEREOSELECTIVE SYNTHESIS OF ANOMERIC BETA-O-GLYCOPYRANOSYLCARBAMATES FROM ISOCYANATES", Synthesis, (11), 1996, pp. 1309
84. DOWELL RI; SPRINGER CJ; DAVIES DH; HADLEY EM; BURKE PJ; BOYLE FT; MELTON RG; CONNORS TA; BLAKEY DC; MAUGER AB
    NEW MUSTARD PRODRUGS FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY - ALTERNATIVES TO THE AMIDE LINK
    Journal of medicinal chemistry
    
    R.I. Dowell et al., "NEW MUSTARD PRODRUGS FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY - ALTERNATIVES TO THE AMIDE LINK", Journal of medicinal chemistry, 39(5), 1996, pp. 1100-1105
85. BLAKEY DC; BURKE PJ; DAVIES DH; DOWELL RI; EAST SJ; ECKERSLEY KP; FITTON JE; MCDAID J; MELTON RG; NICULESCUDUVAZ IA; PINDER PE; SHARMA SK; WRIGHT AF; SPRINGER CJ
    ZD2767, AN IMPROVED SYSTEM FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY THAT RESULTS IN TUMOR REGRESSIONS IN COLORECTAL TUMOR XENOGRAFTS
    Cancer research
    
    D.C. Blakey et al., "ZD2767, AN IMPROVED SYSTEM FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY THAT RESULTS IN TUMOR REGRESSIONS IN COLORECTAL TUMOR XENOGRAFTS", Cancer research, 56(14), 1996, pp. 3287-3292
86. DENNY WA; WILSON WR; HAY MP
    RECENT DEVELOPMENTS IN THE DESIGN OF BIOREDUCTIVE DRUGS
    British Journal of Cancer
    
    W.A. Denny et al., "RECENT DEVELOPMENTS IN THE DESIGN OF BIOREDUCTIVE DRUGS", British Journal of Cancer, 74, 1996, pp. 32-38
87. HOUBA PHJ; LEENDERS RGG; BOVEN E; SCHEEREN JW; PINEDO HM; HAISMA HJ
    CHARACTERIZATION OF NOVEL ANTHRACYCLINE PRODRUGS ACTIVATED BY HUMAN BETA-GLUCURONIDASE FOR USE IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY
    Biochemical pharmacology
    
    P.H.J. Houba et al., "CHARACTERIZATION OF NOVEL ANTHRACYCLINE PRODRUGS ACTIVATED BY HUMAN BETA-GLUCURONIDASE FOR USE IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY", Biochemical pharmacology, 52(3), 1996, pp. 455-463
88. RODRIGUES ML; CARTER P; WIRTH C; MULLINS S; LEE A; BLACKBURN BK
    SYNTHESIS AND BETA-LACTAMASE-MEDIATED ACTIVATION OF A CEPHALOSPORIN-TAXOL PRODRUG
    Chemistry & biology
    
    M.L. Rodrigues et al., "SYNTHESIS AND BETA-LACTAMASE-MEDIATED ACTIVATION OF A CEPHALOSPORIN-TAXOL PRODRUG", Chemistry & biology, 2(4), 1995, pp. 223-227
89. CONNORS TA; KNOX RJ
    PRODRUGS IN CANCER-CHEMOTHERAPY
    Stem cells
    
    T.A. Connors e R.J. Knox, "PRODRUGS IN CANCER-CHEMOTHERAPY", Stem cells, 13(5), 1995, pp. 501-511
90. DEONARAIN MP; SPOONER RA; EPENETOS AA
    GENETIC DELIVERY OF ENZYMES FOR CANCER-THERAPY
    Gene therapy
    
    M.P. Deonarain et al., "GENETIC DELIVERY OF ENZYMES FOR CANCER-THERAPY", Gene therapy, 2(4), 1995, pp. 235-244
91. CONNORS TA
    THE CHOICE OF PRODRUGS FOR GENE DIRECTED ENZYME PRODRUG THERAPY OF CANCER
    Gene therapy
    
    T.A. Connors, "THE CHOICE OF PRODRUGS FOR GENE DIRECTED ENZYME PRODRUG THERAPY OF CANCER", Gene therapy, 2(10), 1995, pp. 702-709
92. SPRINGER CJ; NICULESCUDUVAZ I
    ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) WITH MUSTARD PRODRUGS
    Anti-cancer drug design
    
    C.J. Springer e I. Niculescuduvaz, "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) WITH MUSTARD PRODRUGS", Anti-cancer drug design, 10(5), 1995, pp. 361-372
93. MURRAY JC; CARMICHAEL J
    TARGETING SOLID TUMORS - CHALLENGES, DISAPPOINTMENTS, AND OPPORTUNITIES
    Advanced drug delivery reviews
    
    J.C. Murray e J. Carmichael, "TARGETING SOLID TUMORS - CHALLENGES, DISAPPOINTMENTS, AND OPPORTUNITIES", Advanced drug delivery reviews, 17(1), 1995, pp. 117-127
94. MINTON NP; MAUCHLINE ML; LEMMON MJ; BREHM JK; FOX M; MICHAEL NP; GIACCIA A; BROWN JM
    CHEMOTHERAPEUTIC TUMOR TARGETING USING CLOSTRIDIAL SPORES
    FEMS microbiology reviews
    
    N.P. Minton et al., "CHEMOTHERAPEUTIC TUMOR TARGETING USING CLOSTRIDIAL SPORES", FEMS microbiology reviews, 17(3), 1995, pp. 357-364
95. ROGERS GT; BURKE PJ; SHARMA SK; KOODIE R; BODEN JA
    PLASMA-CLEARANCE OF AN ANTIBODY-ENZYME CONJUGATE IN ADEPT BY MONOCLONAL ANTI-ENZYME - ITS EFFECT ON PRODRUG ACTIVATION IN-VIVO
    British Journal of Cancer
    
    G.T. Rogers et al., "PLASMA-CLEARANCE OF AN ANTIBODY-ENZYME CONJUGATE IN ADEPT BY MONOCLONAL ANTI-ENZYME - ITS EFFECT ON PRODRUG ACTIVATION IN-VIVO", British Journal of Cancer, 72(6), 1995, pp. 1357-1363
96. BLAKEY DC; DAVIES DH; DOWELL RI; EAST SJ; BURKE PJ; SHARMA SK; SPRINGER CJ; MAUGER AB; MELTON RG
    ANTITUMOR EFFECTS OF AN ANTIBODY-CARBOXYPEPTIDASE G2 CONJUGATE IN COMBINATION WITH PHENOL MUSTARD PRODRUGS
    British Journal of Cancer
    
    D.C. Blakey et al., "ANTITUMOR EFFECTS OF AN ANTIBODY-CARBOXYPEPTIDASE G2 CONJUGATE IN COMBINATION WITH PHENOL MUSTARD PRODRUGS", British Journal of Cancer, 72(5), 1995, pp. 1083-1088
97. ANLEZARK GM; MELTON RG; SHERWOOD RF; WILSON WR; DENNY WA; PALMER BD; KNOX RJ; FRIEDLOS F; WILLIAMS A
    BIOACTIVATION OF DINITROBENZAMIDE MUSTARDS BY AN ESCHERICHIA-COLI-B NITROREDUCTASE
    Biochemical pharmacology
    
    G.M. Anlezark et al., "BIOACTIVATION OF DINITROBENZAMIDE MUSTARDS BY AN ESCHERICHIA-COLI-B NITROREDUCTASE", Biochemical pharmacology, 50(5), 1995, pp. 609-618
98. SVENSSON HP; WALLACE PM; SENTER PD
    SYNTHESIS AND CHARACTERIZATION OF MONOCLONAL ANTIBODY-BETA-LACTAMASE CONJUGATES
    Bioconjugate chemistry
    
    H.P. Svensson et al., "SYNTHESIS AND CHARACTERIZATION OF MONOCLONAL ANTIBODY-BETA-LACTAMASE CONJUGATES", Bioconjugate chemistry, 5(3), 1994, pp. 262-267
99. BAGSHAWE KD; SHARMA SK; SPRINGER CJ; ROGERS GT
    ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - REVIEW
    Annals of oncology
    
    K.D. Bagshawe et al., "ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) - REVIEW", Annals of oncology, 5(10), 1994, pp. 879-891
100. MICHAEL NP; BREHM JK; ANLEZARK GM; MINTON NP
     PHYSICAL CHARACTERIZATION OF THE ESCHERICHIA-COLI-B GENE ENCODING NITROREDUCTASE AND ITS OVER-EXPRESSION IN ESCHERICHIA-COLI K12
     FEMS microbiology letters
     
     N.P. Michael et al., "PHYSICAL CHARACTERIZATION OF THE ESCHERICHIA-COLI-B GENE ENCODING NITROREDUCTASE AND ITS OVER-EXPRESSION IN ESCHERICHIA-COLI K12", FEMS microbiology letters, 124(2), 1994, pp. 195-202